Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab.
Sze-Wen TingYi-Cheng ChenYu-Huei HuangPublished in: Clinical drug investigation (2018)
The study outcomes indicate that ustekinumab could be safe for psoriasis patients since none developed persistent hepatitis or acute liver failure during therapy. However, the re-appearance of plasma HBV DNA requires appropriate monitoring of HBV viral load during ustekinumab treatment.